The Patent Finder
LB

Lakefront Biotherapeutics

First filing 2009
OverviewNotableFeesChangesFamiliesPatent listSources & methods

32 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.

The next US patent term in the Lakefront Biotherapeutics portfolio ends in Nov 2029, and more of its terms end in 2032 (8) than in any other year. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Nov 2029
Next term end
16
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders US 9,249,141
The most cited patent in this portfolio, cited by 51 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2034.
Ends Mar 2034 · High confidence
Also notable
Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases US 8,802,682
Cited by 32 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Ends Jul 2032 · High confidence
Also notable
Novel Dihydropyrimidinoisoquinolinones and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders. US 8,927,543
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2032.
Ends Dec 2032 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 8, 2027
    The maintenance fee for 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-Dione Derivatives as Adamts Inhibitors for the Treatment of Osteoarthritis (US 11,718,588) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
  • 1 fee due May 26, 2027
    The maintenance fee for 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-Dione Derivatives as Adamts Inhibitors for the Treatment of Osteoarthritis (US 10,487,060) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
  • 2 fees due Jul 7 to 26, 2027 · next Jul 7
  • 3 fees due Aug 2 to 25, 2027 · next Aug 2

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The largest of its 16 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders (2014)5 in forceto Mar 2034
5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-Dione Derivatives as Adamts Inhibitors for the Treatment of Osteoarthritis4 in forceto Dec 2035
Novel Dihydropyrimidinoisoquinolinones and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders.4 in forceto Dec 2032
Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases (2012)3 in forceto Jul 2032
Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders (2020)2 in forceto Oct 2038

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,242,274Triazolopyridine Kinase Inhibitors Useful for the Treatment of Degenerative and Inflammatory Diseases
In force
 · High confidence
In forceHigh confidence
US 8,663,930Methods and Means for Treatment of Osteoarthritis
In force
 · High confidence
In forceHigh confidence
US 9,951,337Methods and Means for Treatment of Osteoarthritis
In force
 · High confidence
In forceHigh confidence
US 8,796,457Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
In force
 · High confidence
In forceHigh confidence
US 9,505,754Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
In force
 · High confidence
In forceHigh confidence
US 8,975,406Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
In force
 · High confidence
In forceHigh confidence
US 9,241,931Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
In force
 · High confidence
In forceHigh confidence
US 9,987,272Novel Compound Useful for the Treatement of Degenerative and Inflammatory Diseases
In force
 · High confidence
In forceHigh confidence
US 8,802,682Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
In force
 · High confidence
In forceHigh confidence
US 8,927,543Novel Dihydropyrimidinoisoquinolinones and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders.
In force
 · High confidence
In forceHigh confidence
10 of 32 patents shown.
Pro members see all 32.
Pro members: see all 32 patents
Also on record, not counted in the 32: 3 applications pending. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited